Spots Global Cancer Trial Database for stage iii breast cancer
Every month we try and update this database with for stage iii breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer | NCT03102866 | Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Best Practice Exercise Interv... Quality-of-Life... Questionnaire A... | - | Ohio State University Comprehensive Cancer Center | |
| Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery | NCT03113825 | Primary Invasiv... Carcinoma Breas... Breast Cancer F... Carcinoma, Duct... Stage II Breast... Stage I Breast ... Stage III Breas... | Investigational... AVB-620 | 18 Years - | Avelas Biosciences, Inc. | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | NCT00003680 | Breast Cancer | CMF regimen cyclophosphamid... fluorouracil methotrexate tamoxifen citra... thiotepa peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors | NCT03284346 | Cancer Survivor No Evidence of ... Obesity Overweight Prostate Carcin... Sedentary Lifes... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Exercise Interv... Exercise Interv... Laboratory Biom... Monitoring Devi... Quality-of-Life... Questionnaire A... | 18 Years - | University of Southern California | |
| Capecitabine in Women With Operable Breast Cancer | NCT00148720 | Invasive Breast... Primary Invasiv... Stage I Breast ... Stage II Breast... Stage III Breas... | Capecitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer | NCT00262834 | Breast Cancer Stage I Breast ... Stage II Breast... Stage III Breas... | vorinostat conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | NCT00136539 | Breast Cancer | Herceptin Taxol Adriamycin Cytoxan | 18 Years - | Dana-Farber Cancer Institute | |
| Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer | NCT03139435 | Peripheral Neur... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Biopsy Questionnaire A... Ultrasound Tomo... | - | Wake Forest University Health Sciences | |
| Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. | NCT00910884 | Breast Cancer | laboratory biom... therapeutic die... | 18 Years - 70 Years | Brabant Research | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy | NCT00006121 | Breast Cancer | oxaliplatin | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | NCT01831076 | Breast Cancer Stage II Breast... Stage III Breas... | Exemestane Exemestane and ... | 50 Years - | University of Colorado, Denver | |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer | NCT01907529 | Stage III Breas... | docetaxel, epir... docetaxel, epir... | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients | NCT05535192 | Breast Cancer Stage III Breas... Breast Cancer F... Stage I Breast ... Stage II Breast... | THRIVE Health Educatio... | 65 Years - | Dana-Farber Cancer Institute | |
| Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) | NCT01988571 | Breast Cancer Lymphoma | Atorvastatin Placebo | 21 Years - 100 Years | Wake Forest University Health Sciences | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | NCT03971409 | Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Invasive Breast... Recurrent Breas... Triple-Negative... Unresectable Br... | Anti-OX40 Antib... Avelumab Binimetinib Utomilumab Liposomal Doxor... Sacituzumab Gov... | 18 Years - | University of California, San Francisco | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | NCT00198237 | Breast Cancer | docetaxel & cap... | 18 Years - | Indiana University | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients | NCT05535192 | Breast Cancer Stage III Breas... Breast Cancer F... Stage I Breast ... Stage II Breast... | THRIVE Health Educatio... | 65 Years - | Dana-Farber Cancer Institute | |
| Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer | NCT00994968 | Breast Cancer | cyclophosphamid... docetaxel doxorubicin hyd... tegafur-gimerac... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer. | NCT06087120 | Breast Cancer F... Stage II Breast... Stage III Breas... HER2-positive B... Triple Negative... | 18 Years - | Gene Solutions | ||
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners | NCT03112668 | Malignant Femal... Malignant Hepat... Partner Stage III Breas... Stage III Cervi... Stage III Color... Stage III Lung ... Stage III Prost... Stage III Skin ... Stage III Uteri... Stage IIIA Brea... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Lung... Stage IIIA Skin... Stage IIIA Uter... Stage IIIB Brea... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Lung... Stage IIIB Skin... Stage IIIB Uter... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Skin... Stage IIIC Uter... Stage IV Breast... Stage IV Cervic... Stage IV Colore... Stage IV Lung C... Stage IV Prosta... Stage IV Skin M... Stage IV Uterin... Stage IVA Cervi... Stage IVA Color... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Color... Stage IVB Uteri... | Cognitive Behav... Quality-of-Life... Questionnaire A... Survey Administ... | 18 Years - | Rutgers, The State University of New Jersey | |
| Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | NCT04985357 | Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin... | 18 Years - | Travera Inc | ||
| HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | NCT03387553 | Breast Cancer Breast Cancer F... Breast Cancer, ... Invasive Breast... HER2-positive B... HER2 Positive B... Stage II Breast... Stage III Breas... | Dendritic Cell ... Neoadjuvant Che... Curative Surger... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer | NCT00003418 | Breast Cancer | exemestane tamoxifen citra... | - | National Cancer Institute (NCI) | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer | NCT01907529 | Stage III Breas... | docetaxel, epir... docetaxel, epir... | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | NCT05512364 | ER-positive Bre... HER2-negative B... Stage IIB Breas... Stage III Breas... | Elacestrant Tamoxifen Letrozole 2.5mg Anastrozole 1mg Exemestane 25 M... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | NCT01194427 | Stage I Breast ... Stage II Breast... Stage III Breas... Invasive Breast... | Vorinostat and ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00654836 | Breast Cancer | bevacizumab Carboplatin ABI-007 | 18 Years - | Loyola University | |
| Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer | NCT00002864 | Breast Cancer | octreotide acet... tamoxifen citra... | - 120 Years | Canadian Cancer Trials Group | |
| Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | NCT00003680 | Breast Cancer | CMF regimen cyclophosphamid... fluorouracil methotrexate tamoxifen citra... thiotepa peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Acupuncture Pilot Study for Cancer-related Cognitive Function | NCT04007770 | Stage I Breast ... Stage II Breast... Stage III Breas... Stage I Colorec... Stage II Colore... Stage III Color... Gynecologic Can... Stage I Gynecol... Stage II Gyneco... Stage III Gynec... Stage I Prostat... Stage II Prosta... Stage III Prost... | Acupuncture Sham Acupunctur... 16 week waiting... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer | NCT01431196 | Stage II Breast... Stage III Breas... | Autologous dend... | 18 Years - 75 Years | Clinica Universidad de Navarra, Universidad de Navarra | |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00654836 | Breast Cancer | bevacizumab Carboplatin ABI-007 | 18 Years - | Loyola University | |
| Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | NCT00198237 | Breast Cancer | docetaxel & cap... | 18 Years - | Indiana University | |
| Ask Questions (ASQ):Implementation of a Communication Intervention | NCT05025748 | Stage II Breast... Stage III Breas... Stage IV Breast... Stage II Colore... Stage III Color... Stage IV Colore... Stage II Lung C... Stage III Lung ... Stage IV Lung C... Stage II Prosta... Stage III Prost... Stage IV Prosta... Stage II Ovaria... Stage III Ovari... Stage IV Ovaria... Stage II Cervic... Stage III Cervi... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Stage II Kidney... Stage III Kidne... Stage IV Kidney... | Behavioral Inte... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer | NCT02157051 | HER2 Negative B... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage III Breas... | CD105/Yb-1/SOX2... Laboratory Biom... | 18 Years - | University of Washington | |
| Preoperative Herceptin and Navelbine for Breast Cancer | NCT00148681 | Breast Cancer Stage II Breast... Stage III Breas... | Herceptin Navelbine Doxorubicin Cyclophosphamid... Paclitaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer. | NCT06087120 | Breast Cancer F... Stage II Breast... Stage III Breas... HER2-positive B... Triple Negative... | 18 Years - | Gene Solutions | ||
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | NCT03364348 | HER2 Positive B... Recurrent Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Utomilumab Trastuzumab Ado-Trastuzumab... | 18 Years - | Stanford University | |
| Researching the Effect of Exercise on Cancer | NCT04589468 | Breast Cancer Prostate Cancer Colorectal Canc... Stage I Breast ... Stage II Breast... Stage III Breas... Stage I Prostat... Stage II Prosta... Stage III Prost... Stage I Colorec... Stage II Colore... Stage III Color... | Exercise | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer | NCT03091842 | Cancer Survivor Central Obesity Estrogen Recept... Postmenopausal Progesterone Re... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Exercise Interv... Exercise Interv... Exercise Interv... Informational I... Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | University of Southern California | |
| Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease | NCT00003357 | Breast Cancer | GM2-KLH vaccine QS21 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Preoperative Herceptin and Navelbine for Breast Cancer | NCT00148681 | Breast Cancer Stage II Breast... Stage III Breas... | Herceptin Navelbine Doxorubicin Cyclophosphamid... Paclitaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer | NCT03139435 | Peripheral Neur... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Biopsy Questionnaire A... Ultrasound Tomo... | - | Wake Forest University Health Sciences | |
| Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery | NCT03113825 | Primary Invasiv... Carcinoma Breas... Breast Cancer F... Carcinoma, Duct... Stage II Breast... Stage I Breast ... Stage III Breas... | Investigational... AVB-620 | 18 Years - | Avelas Biosciences, Inc. | |
| Living Well After Breast Surgery | NCT03834532 | Breast Cancer F... Stage I Breast ... Stage II Breast... Stage III Breas... Ductal Carcinom... Ductal Breast C... Lobular Breast ... | Breast reconstr... Educational web... | 18 Years - | University of Texas at Austin |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
